Review

Thromboinflammation in COVID-19 acute lung injury

William Beau Mitchell

Hemostasis and Thrombosis, Division of Hematology/Oncology, Children's Hospital at Montefiore, Bronx, NY, USA

Educational aims

The reader will be able to appreciate:

- Thromboinflammation is a component of COVID-19 acute lung injury.
- Thromboinflammation has a multifactorial aetiology.
- There are multiple potential therapies for thromboinflammation, some already in clinical trials, that may benefit COVID-19 acute lung injury.

Article info

Keywords:
COVID-19
Acute lung injury
Thrombosis
Inflammation

Abstract

Since the initial description in 2019, the novel coronavirus SARS-CoV-2 infection (COVID-19) pandemic has swept the globe. The most severe form of the disease presents with fever and shortness of breath, which rapidly deteriorates to respiratory failure and acute lung injury (ALI). COVID-19 also presents with a severe coagulopathy with a high rate of venous thromboembolism. In addition, autopsy studies have revealed co-localized thrombosis and inflammation, which is the signature of thromboinflammation, within the pulmonary capillary vasculature. While the majority of published data is on adult patients, there are parallels to pediatric patients. In our experience as a COVID-19 epicenter, children and young adults do develop both the coagulopathy and the ALI of COVID-19. This review will discuss COVID-19 ALI from a hematological perspective with discussion of the distinct aspects of coagulation that are apparent in COVID-19. Current and potential interventions targeting the multiple thromboinflammatory mechanisms will be discussed.

© 2020 Elsevier Ltd. All rights reserved.

Introduction

Since the initial description in 2019, the novel coronavirus SARS-CoV-2 infection (COVID-19) pandemic has swept the globe, impacting almost every country with both human and economic loss. The most severe form of disease presents with fever and shortness of breath, which rapidly deteriorates to respiratory failure. At several COVID-19 hotspots around the world the healthcare delivery systems have been overwhelmed by the number of patients requiring ventilatory support for respiratory failure and acute lung injury (ALI). As more data is emerging it has become apparent that COVID-19 also presents with a severe coagulopathy [1]. This coagulopathy is distinct from disseminated intravascular coagulation. COVID-19 patients typically have high fibrinogen, normal or modestly prolonged prothrombin time and activated partial thromboplastin time, platelet count >100 x 10^9/mL, and do not typically bleed. In addition to the reported intravascular thrombosis, COVID-19 patients also frequently thrombose dialysis and ECMO circuits despite anticoagulation. While the majority of published data is on adult patients, there are parallels to pediatric patients. Pediatric patients have been reported to have fewer severe symptoms, fewer ICU admissions and fewer deaths from COVID-19 [2,3]. However, in our experience, children and young adults do develop the acute lung injury of COVID-19 and do manifest the severe coagulopathy with increased rate of thrombosis [4].

Based on the few published autopsy studies, which altogether include 16 adults, the primary cause of death in COVID-19 appears to be Acute Lung Injury (ALI) characterized by severe endothelial damage, inflammation and extensive thrombosis of the perivascular capillaries [5–8]. This co-localization of thrombosis and inflammation is a typical feature of ALI from other causes and is an
example of thromboinflammation, which is the convergence of thrombotic and inflammatory processes [9]. Although the hemostatic and immune functions are generally regarded separately, they are linked together by evolution from a single cell type in primitive organisms, the hemocyte, which performs all hemostatic, inflammatory and immune functions. This single-cell system has evolved into the highly complex coagulation cascade, the complement system, and the multicellular immune system. Although these systems are distinct in higher mammals, they remain interconnected and interdependent. Thrombosis evolved as part of the innate immune system as a means of isolating invading organisms. For example, platelets play multiple roles in innate immunity by such varied activities as binding to and removing pathogens directly from circulation [10,11], secreting serotonin to recruit immune cells to sites of infection, and activating neutrophils to produce neutrophil extracellular traps (NETs) [12].

This connection between thrombosis and inflammation is evident in the pathology of COVID-19 ALI. Available studies report mononuclear cell infiltrates around thrombosed small vessels and neutrophils within the fibrin thrombi. The capillary thrombotic component is rich in inflammatory cells including lymphocytes, macrophages and NETs. These findings are the signature of thromboinflammation. This review will discuss the COVID-19 ALI from a hematological perspective with discussion of the distinct aspects of coagulation that are apparent in both the clinical picture and the pulmonary pathology of COVID-19. Current and potential interventions targeting the multiple thromboinflammatory mechanisms will be discussed.

TRIGGERS OF THROMBOINFLAMMATION

Damage to the pulmonary vascular endothelium

Disruption of the pulmonary capillary endothelium is a consistent finding in the reported autopsy cases of COVID-19 ALI. The endothelial damage was reported to be more extensive in COVID-19 ALI than in H1N1-related ALI [7]. The endothelium showed loss of both intercellular junctions and contact with the basement membranes, thus exposing the highly thrombogenic extracellular matrix and basement membrane.

An intact vascular endothelium is a potent anti-thrombotic, and anti-inflammatory barrier [9]. This protective coating of the blood vessels prevents spontaneous activation of coagulation and protects against pathologic thromboses. There are multiple components that confer these protective properties to the endothelium (Table 1). Several components inhibit platelet activation, for example the surface receptor CD39, the secreted prostaglandin PG12, and secreted nitric oxide (NO). PG12 also inhibits leukocyte recruitment and activation, while NO also limits leukocyte adhesion to the endothelium. The endothelial surface is also normally decorated with tissue factor pathway inhibitor (TFPI), which inhibits initiation of coagulation, and glycosaminoglycans, which inhibit binding of prothrombotic factors. Lastly, endothelial thrombomodulin activates the potent antithrombotic protein C pathway. The severe damage to the endothelium seen in COVID-19 ALI would be expected to disrupt all of these protective mechanisms, leaving the capillaries vulnerable to thrombosis and inflammation.

Thrombin generation

The dense fibrin-rich microthrombi of the pulmonary capillaries reported in COVID-19 ALI indicate high activity of thrombin, which is the primary driver of coagulation and fibrin formation. The high thrombin activity is reflected by the high levels of thrombin-antithrombin (TAT) complexes seen in the most severely ill COVID-19 patients [13]. Thrombin is generated through the serial activation of proteases known as the coagulation cascade, or secondary hemostasis [14]. The pathway begins with the activation of tissue factor and the generation of a small amount of thrombin. This thrombin then activates the remainder of the cascade, leading to activation of factor X and amplification of thrombin formation. Thrombin finally generates fibrin from fibrinogen.

In general, thrombin plays multiple roles in thrombosis and inflammation (Table 2) [15]. In its thrombotic role [16], thrombin activates platelets, which serve as the phospholipid surface on which much of coagulation takes place. Thrombin also activates endothelial cells through PAR-1 leading to increased von Willebrand Factor (VWF) secretion from Weibel–Palade bodies. In its inflammatory role, thrombin increases the endothelial surface expression of P-selectin, thereby increasing neutrophil recruitment to the endothelium and subsequent activation. Thrombin also activates leukocytes and endothelial smooth muscle, leading to release of multiple cytokines and upregulation of surface adhesion markers.

Table 1

| Endothelium feature       | Anti-thrombotic Mechanism                                      |
|---------------------------|---------------------------------------------------------------|
| CD39                      | Inhibits platelet activation                                 |
| Prostaglandin PG12        | Inhibits platelet activation                                 |
| Nitric Oxide              | Inhibits platelet activation                                 |
| Tissue Factor Pathway Inhibitor (TFPI) | Inhibits platelet activation |
| Thrombomodulin            | Activates protein C antithrombotic pathway                   |

Table 2

| Function                  | Mechanism                          | Comments                  |
|---------------------------|------------------------------------|---------------------------|
| Drives coagulation        | Proteolytic activation of coagulation factors | Primary driver of the coagulation cascade |
| Generates fibrin          | Proteolysis of fibrinogen          | Final step in the coagulation cascade |
| Activates platelets       | Cleaves PAR1 and PAR4              | Leads to complete granule release |
| Activates endothelial cells | Cleaves PAR1                  | Increases neutrophil recruitment |
| Activates leukocytes      | Cleaves PAR1                      | Releases VWF into circulation |
| Activates endothelial smooth muscle cells | Cleaves PAR1 | Increased adhesion |

Table 3

| Function                  | Mechanism                          | Comments                  |
|---------------------------|------------------------------------|---------------------------|
| Primary hemostasis        | Adheres to VWF and Collagen        | Initiation of hemostasis   |
| Granule content secretion | Platelet activation                | Releases prothrombotic substances |
| PolyP release             | Dense granule secretion            | Initiates contact pathway |
| Leukocyte binding         | P-selectin                         | Increases neutrophil recruitment |
| Neutrophil binding        | P-selectin                         | Activates leukocytes |

Please cite this article as: W. B. Mitchell, Thromboinflammation in COVID-19 acute lung injury, Paediatric Respiratory Reviews, https://doi.org/10.1016/j.prrv.2020.06.004
An early clinical indication of the importance of thrombin in COVID-19 disease was the report from Wuhan showing a survival advantage of those patients who received heparin, which is a potent anti-thrombin agent [17]. In that retrospective study 99 out of 449 patients with severe COVID-19 received heparin for more than 7 days during their hospitalization. In the most severely ill patients (SIC score ≥4) 40% of those who received heparin succumbed, compared to 64% of those who did not (p = 0.029). This 20% survival advantage sparked the clinical use of heparin in severe COVID-19.

In addition to ALI, venous thromboembolism (VTE - deep vein thrombosis and/or pulmonary embolism) is widely reported in COVID-19. Since the Wuhan report heparin has been widely used in COVID-19 with partial success, but several centers have reported VTE rates of up to 30% in critically ill COVID-19 patients [18–22]. This included patients already on prophylactic anticoagulation with heparin. This high rate of failure of prophylactic heparin is in contrast to the expected 5–7% VTE breakthrough for critically ill patients while on prophylactic heparin [23]. Clearly, further anticoagulation is needed for these very ill patients. There are currently multiple clinical trials of anticoagulation in COVID-19 (Table 4).

Platelet activation

Platelet activation underlies thrombus formation. Autopsy analyses of COVID-19 ALI have reported that the alveolar capillaries were filled with fibrin-rich thrombi containing neutrophils, indicating extensive platelet activation. Microthrombi were found extensively in the pre- and post-capillary vessels throughout the lungs. Such extensive thrombosis would be expected to disrupt the normal physiology of oxygen exchange and ventilation, contributing to the COVID-19 ALI. It was also reported that the resident lung megakaryocytes were increased and actively producing platelets [5]. Young platelets have increased coagulation potential and the highest level of granule contents, making them more thrombogenic than older platelets. These resident megakaryocytes may be adding highly thrombogenic platelets to an already hypercoagulable environment.

Platelet activation is the first step in primary hemostasis and is initiated by binding of platelet surface GPIb/IX to von Willebrand factor (VWF) on damaged endothelium. These initial platelets then undergo activation largely by signaling through GP6 binding to collagen. Activated platelets then recruit more platelets and crosslink with them via fibrinogen (and other plasma proteins) binding to activated GPIb/IIa receptors. Activated platelets provide an important membrane surface for the cell-based coagulation cascade and production of thrombin and ultimately fibrin, as well as activation of the contact pathway. There are multiple approved antiplatelet therapies, some of which are in clinical trials against COVID-19 (Table 4).

Platelets also perform several functions beyond hemostasis that are likely contributing to the ALI of COVID-19 (Table 3). Upon activation, platelets secrete hundreds of substances. These include multiple proinflammatory cytokines such as IL-1beta [24] and pro angiogenic factors such as vascular endothelial growth factor (VEGF) [25]. Platelets also release polyphosphate (PolyP) multimers from their dense granules upon activation [26]. The largest of these multimers remain bound to the surface of the platelet and serve as a substrate for the activation of the contact pathway, which plays a role in pathologic thrombus formation. Activated platelets bind to leukocytes and promote leukocyte activation and extravasation [27]. Activated platelets also form aggregates with neutrophils and cause upregulation of MAC-1, which leads to stable neutrophil-endothelium biding [28]. Platelet neutrophil aggregates are frequently seen in thromboinflammation and are reported to be elevated in COVID-19 patients. In transfusion-associated ALI, activated platelets induce neutrophils to generate NETs, which are both proinflammatory and procoagulant [29]. NETs were markedly increased in the blood of COVID-19 patients [30] and were noted in the pulmonary capillaries of COVID-19 ALI [5].

Infiltration of neutrophils and macrophages

Neutrophils and other inflammatory cells were observed within the capillary thrombi in COVID-19 ALI, and there was indication of NETs formation. Neutrophils are recruited to growing thrombi by activated platelets. Activated platelets also induce neutrophils to form NETs [28]. NETs are the organized extrusion of the chromatin of mature neutrophils [31]. NETs have many functions, including anti-bacterial and prothrombotic activity. NETs also damage the endothelium and inhibit fibrinolysis by trapping TFPI, which makes them highly thrombogenic. Cell free DNA is seen in the sera of COVID-19 patients, indicating NETs formation [30]. Macrophages are also recruited to fibrin thrombi and work to remodel the thrombus as part of the normal healing process [32]. Macrophages within the fibrin clot generate plasmin, which degrades fibrin to produce D-Dimers. Macrophages are also an alternate source of D-Dimer by uptake and degradation of fibrin via CD11b/CD18 (Mac-1) receptors [33]. These macrophage functions likely contribute to the unusually extreme elevation of D-dimers that is a unique feature of COVID-19.

Contact pathway activation

There is a second pathway of coagulation, known as the contact pathway, that is primarily initiated by factor XII binding to PolyP on the activated platelet surface. This pathway is expendable for secondary hemostasis but has been implicated in formation of pathological thrombi and thrombi formation on artificial surfaces [34]. One clue to the activation of the contact pathway in COVID-19 has been the repeated observation of low factor XII levels in very sick patients (personal communication). These low levels may indicate consumption of factor XII during activation of the contact pathway. There is growing interest in targeting the contact pathway for prevention of pathological thrombosis and inflammation, and there are novel anti-contact pathway therapies that could potentially target the thromboinflammation of COVID-19 [35].

THERAPIES FOR THROMBOINFLAMMATION

The pathological findings in COVID-19 ALI paint a highly thrombogenic and inflammatory picture. What can be done to ameliorate or prevent this from occurring? Since the mechanism underlying ALI thromboinflammation is multifactorial there are multiple potential targets for therapy. Given the prominence of the thrombotic microangiopathy in the COVID-19 ALI pathology, those therapies directed at preventing or reversing the coagulopathy of ALI may be efficacious for survival. Due to the multifactorial nature of thromboinflammation multiple complementary anticoagulant/antithrombotic modalities may be needed.

Heparin

Heparin derails the coagulation cascade by deactivating activated factor X, which is the primary producer of thrombin, thereby slowing secondary hemostasis. Since the report from Wuhan suggesting that heparin use was associated with improved survival, most large centers have adopted a prophylactic heparin protocol for COVID-19 patients, as well as criteria for escalation to...
Active clinical trials targeting thromboinflammation.

| Target | NCT number | Title |
|--------|------------|-------|
| Endothelium | NCT04398290 | INOpulse for COVID-19 |
| | NCT04397692 | Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial) |
| | NCT04388683 | Inhaled Nitric Oxide for Preventing Progression in COVID-19 |
| | NCT04383002 | High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients) |
| | NCT04358588 | Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19 |
| | NCT04338828 | Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED |
| Thrombin | NCT04408235 | High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy |
| | NCT04406389 | Anti-coagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) |
| | NCT04401293 | Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients |
| | NCT04397510 | Nebulized Heparin for the Treatment of COVID-19-Induced Lung Injury |
| | NCT04394177 | Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAD ACTION Trial |
| | NCT04393805 | Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto |
| | NCT04377997 | Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19 |
| | NCT04373707 | Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 |
| | NCT04372589 | Antithrombotic Therapy to Ameliorate Syndrome Therapy: A Randomised Controlled Trial. |
| | NCT04367831 | Intermediate or Prophylactic-Dose Anticoagulation in Venous or Arterial Thromboembolism in Severe COVID-19 |
| | NCT04366960 | Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients |
| | NCT04362085 | Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care |
| | NCT04360824 | Covid-19-Associated Coagulopathy |
| | NCT04359277 | A Randomized Trial of Anticoagulation Strategies in COVID-19 |
| | NCT04359212 | Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19 |
| | NCT04345648 | Preventing COVID-19 Complications With Low- and High- dose Anticoagulation |
| | NCT04344756 | Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort |
| | NCT04343001 | Coronavirus Response - Active Support for Hospitalised Covid-19 Patients |
| | NCT04333407 | Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. |
| Platelets | NCT04391179 | Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICE) in COVID-19 |
| | NCT04363840 | The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations |
| | NCT04368377 | Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19 |
| | NCT04365309 | Protective Effect of Aspirin on COVID-19 Patients |

Heparin is a potent anticoagulant, but it also has other potential roles in thromboinflammation and ALI. In an animal model of ALI, local heparin attenuated acute lung injury (ALI) in lung tissue by decreasing multiple proinflammatory pathways, including decreasing production of interleukin 6 and tumor necrosis factor alpha [36]. These cytokines are markedly elevated in critically ill COVID-19 patients. In alveolar macrophages heparin reduced expression of procoagulant genes for transforming growth factor beta and nuclear factor kappa B. Heparin also protects the endothelium from NETs and histones, sequesters cytokines and complement, and protects against recruitment of inflammatory cells [37,38]. There is also data that heparin interacts with spike proteins of several viruses, including the SARS-CoV-2 spike protein receptor binding domain, suggesting that it may be able to modulate that protein’s interactions with the endothelium [39]. Of note, aerosolized heparin has been explored in human ALI with results indicating decreased inflammation and thrombosis [40,41]. As more data is reported a clearer picture of the effect of heparin on COVID-19 ALI, coagulopathy, and survival will emerge. At the time of writing there are 19 clinical trials of heparin in COVID-19 listed on clinicaltrials.gov (Table 4).

Direct anti-thrombin and anti-Xa inhibitors

These agents bind directly to and inhibit thrombin or factor Xa. They are attractive because of the ease of administration and no requirement for monitoring. However, there is limited data for their use in children who way less than 40 kg. There is no large population study yet using these agents in COVID-19, but theoretically they would have both anticoagulation and anti-inflammatory activity.

Anti-platelet agents

Given the microangiopathy of COVID-19 ALI, platelets are an attractive drug target. There are already several types of anti-platelet agents available. To be most effective however, the agent of choice may need to suppress platelet granule release in order to decrease the secondary effects of platelet activation. Aspirin will not do this, but P2y12 inhibitors and GPIIb/IIIa inhibitors could in high enough doses. At time of writing there are four clinical trials of antiplatelet agents in COVID-19 listed on clinicaltrials.gov (Table 4).

Contact pathway inhibitors

The contact pathway is an attractive anticoagulation target since loss of contact pathway function does not lead to bleeding in animals or humans. However, initiation of the contact pathway plays a role in pathological thrombosis in mouse models. Thus, the contact pathway is dispensable for hemostasis but essential for certain types of thrombosis. The contact factor pathway also has an important inflammatory role as it produces bradykinin, a potent inflammatory protein. It is not known at this time whether the contact pathway plays a role in COVID-19 ALI. Multiple factor XI and XII inhibitors are under development and a few are approved for limited indications. At the time of writing there are no contact pathway inhibitor trials listed in clinicaltrials.gov.
SUMMARY AND CONCLUSIONS

Severe COVID-19 is characterized by ALI and respiratory failure. While current pathology reports are all of adult cases, in our experience pediatric patients also acquire severe COVID-19 and require mechanical ventilation. It seems likely that children have a similar ALI pathology, although their endothelium may be healthier to begin with. The ALI of COVID-19 has a severe thromboinflammatory component characterized by neutrophil and lymphocyte infiltrates into fibrous thrombi with evidence of NETs formation. Multiple thrombotic pathways likely converge to create the thromboinflammation of COVID-19 ALI, including endothelial damage, thrombin activation, platelet activation, NETs formation, and contact pathway activation. These pathways offer multiple targets for mitigation of COVID-19 coagulopathy and may potentially ameliorate the ALI contribution to morbidity and mortality in COVID-19.

DIRECTIONS FOR FUTURE RESEARCH

- Studies on the coagulopathy of COVID-19 in children are needed.
- Studies to determine optimal prophylactic heparin anticoagulation regimen to prevent DVT/PE are needed.
- Studies of antithrombotic agents are needed.
- Studies of other antithrombotic therapies, including direct thrombin inhibitors, direct factor Xa inhibitors and contact pathway inhibitors should be considered.

Acknowledgement

I would like to thank Deepa Manwani, MD for critical review of the manuscript.

References

[1] Iba T, Levy JH, Marcel Connors, Jean Marie Thachil, Jecko. Coagulopathy of Coronavirus Disease 2019. Crit Care Med. 2020.
[2] Castagnoli R, Votto M, Licari A, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatrics 2020.
[3] Parri N, Lenge M, Buonsenso D. Children with covid-19 in pediatric emergency departments in Italy. N Engl J Med 2020.
[4] Chao JY, Derespina KR, Herold BC, et al. Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 (COVID-19) at a Tertiary Care Medical Center in New York City. J Pediatrics
[5] Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. medRxiv. 2020.
[6] Varga F, Flammier AJ, Seiger P, et al. Endothelial cell infection and endothelitis in COVID-19. Lancet 2020;395(10234):1417–8.
[7] Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 2020.
[8] Barton LM, Duval EJ, Strobeg E, Ghosh S. Mukhopadhyay S. COVID-19 Autopsies, Oklahoma, USA. Am J Clin Pathol 2020;153(6):725–33.
[9] Jackson SP, Darbouset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 2019;133(9):906–18.
[10] Semple JW, Freedman J. Platelets and innate immunity. Cell Mol Life Sci 2010;67(4):499–511.
[11] Gaertner F, Ahmad Z, Rosenberger G, et al. Migrating platelets are mechano-sensors that collect and bundle bacteria. Cell 2017;171(6):1368–1382. e1323.
[12] Iannacone M. Platelet-mediated modulation of adaptive immunity. Semin Immunol 2016;28(6):555–60.
[13] Jin X, Duan Y, Bao T, et al. The values of coagulation function in COVID-19 patients. medRxiv. 2020. 2020:2004.2020.20077842.
[14] Hoffman M, Monroe 3rd DM. A cell-based model of hemorrhage. Thromb Haemost 2001;85(6):598–65.
[15] Posma JJ, Posthuma JJ, Sproot HM. Coagulation and non-coagulation effects of thrombolysis. J Thromb Haemost 2016;14:10:1908–16.
[16] Negrier C, Shima M, Hoffman M. The central role of thrombin in bleeding disorders. Blood Rev 2019;38:100582.
[17] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18(5):1094–9.
[18] Demelo-Rodríguez P, Cervilla-Muñoz E, Oríndez-Ortega L, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res 2020;192:23–6.
[19] Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;1–10.
[20] Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020.
[21] Littjs JF, Leclerc M, Chochos C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020.
[22] Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19: a multicenter cohort study. Thromb Res 2020;191:9–14.
[23] Lim W, Meade M, Lauzier F, et al. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients. Crit Care Med 2015;43(2):401–10.
[24] Lundeborg S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin Ibeta synthesis. J Biol Chem 2001;154(3):485–90.
[25] Battelli EM, Markens BA, Iannaccone M, Tsafrir D, et al. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 2011;118(5):1359–69.
[26] Müller F, Mutsch J, Schenkenberg R, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009;139(6):1143–56.
[27] Rossaint J, Margraf A, Zarbock A. Role of platelets in leukocyte recruitment and resolution of inflammation. Front Immunol 2018;9:2712.
[28] Lisman T. Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease. Cell Tissue Res 2018;371(3):567–76.
[29] Cauldri B, A Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 2012;122(7):2661–71.
[30] Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight 2020.
[31] Brimkamp V. Neutrophil extracellular traps in the second decade. J Innate Immun 2018;10:5–6:414–21.
[32] Manghjabhoy S, Johnson TA, Duru N, et al. Fibrogenesis and inflammation in venous thrombus resolution. Front Immunol 2019;10:1348.
[33] Loscalzo J. The macrophage and fibrinolysis. Semin Thromb Hemost 2019;45(5):676–7.
[34] Maas C, Renne T. Coagulation factor XII in thrombosis and inflammation. Blood 2018;131(17):1903–9.
[35] DeLoughery GP, Olsin SR, Puy C, McCarty OJ, Shatzel JJ. The safety and efficacy of novel agents targeting factors XI and XII in early phase human trials. Semin Thromb Hemost 2019;45(5):502–8.
[36] Chimenti I, Campbruí-Rimbals M, Guillamat-Prats R, et al. Nebulized heparin attenuates pulmonary coagulopathy and inflammation through macrophages in a rat model of acute lung injury. Thromb Haemost 2017;117(1):2125–34.
[37] Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci 2015;2015:507151.
[38] Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008;122(6):743–52.
[39] Mycroft-West C, Su D, Ely S, et al. The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S Receptor Binding Domain undergoes conformational change upon heparin binding. bioRxiv. 2020:2020.2002.2009.711093.
[40] Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD. Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. In: Crit Care 14.2010:445.
[41] Dixon B, Santamaria JD, Campbell DJ. A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 2008;12(3):864.